Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Baniel

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Clinical Genitourinary Cancer|November 22, 2017
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient PopulationAndrea Necchi, Gregory R Pond, Sumanta K Pal, et al.
Clinical Genitourinary Cancer|September 20, 2017
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract TumorsJorge D Ramos, Jonathan T Wingate, Roman Gulati, et al.
Clinical Genitourinary Cancer|December 14, 2020
Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy RegimensOlivia A Do, Lorin A Ferris, Sarah K Holt, et al.
Urologic Oncology|July 15, 2020
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survivalCamilla M Grunewald, Alina Henn, Matthew D Galsky, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Urologic Oncology|September 19, 2016
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancerJ Alfred Witjes, Guido Dalbagni, Robert J Karnes, et al.
European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
World Journal of Urology|March 13, 2021
Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancerDavid D'Andrea, Francesco Soria, Anne J Grotenhuis, et al.
BJU International|September 4, 2012
Predictors of cancer-specific mortality after disease recurrence following radical cystectomyMichael Rink, Daniel J Lee, Matthew Kent, et al.
BJU International|October 16, 2015
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-GuérinPaolo Gontero, Richard Sylvester, Francesca Pisano, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Clinical Genitourinary Cancer|November 22, 2017
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient PopulationAndrea Necchi, Gregory R Pond, Sumanta K Pal, et al.
Clinical Genitourinary Cancer|September 20, 2017
Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract TumorsJorge D Ramos, Jonathan T Wingate, Roman Gulati, et al.
Clinical Genitourinary Cancer|December 14, 2020
Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy RegimensOlivia A Do, Lorin A Ferris, Sarah K Holt, et al.
Urologic Oncology|July 15, 2020
Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survivalCamilla M Grunewald, Alina Henn, Matthew D Galsky, et al.
Frontiers in Oncology|December 5, 2018
Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC DatabaseGabriella Del Bene, Fabio Calabrò, Diana Giannarelli, et al.
Urologic Oncology|September 19, 2016
The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancerJ Alfred Witjes, Guido Dalbagni, Robert J Karnes, et al.
European Urology Oncology|August 15, 2019
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract CancersNieves Martinez Chanza, Lillian Werner, Elizabeth Plimack, et al.
World Journal of Urology|March 13, 2021
Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancerDavid D'Andrea, Francesco Soria, Anne J Grotenhuis, et al.
BJU International|September 4, 2012
Predictors of cancer-specific mortality after disease recurrence following radical cystectomyMichael Rink, Daniel J Lee, Matthew Kent, et al.
BJU International|October 16, 2015
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-GuérinPaolo Gontero, Richard Sylvester, Francesca Pisano, et al.
Pageof 15